Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo

TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO: Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to support canine neurological health. The company also disclosed a new research collaboration with the University of Tokyo aimed at further validating the clinical benefits of DHA in dogs with idiopathic epilepsy.

A-DHA-PT™ was developed to address growing clinical interest in nutritional approaches to neurological conditions in companion animals. Each compact 13 mm capsule delivers a high dose of over 150 mg of DHA, enabling efficient administration while minimizing pill burden for dogs. The product is available in bags containing 120 capsules.

The product's formulation is based on prior academic research* and has been developed under the scientific supervision of Dr. Tomohiro Yonezawa, Associate Professor of the University of Tokyo. A-DHA-PT™ is manufactured in Japan using pharmaceutical-grade raw materials under strict quality and safety standards.

* Effects of high-dose docosahexaenoic acid supplementation as an add-on therapy for canine idiopathic epilepsy: A pilot study. Open Vet J. 2023 Jul; 13(7): 942-947.

Research Collaboration on Canine Idiopathic Epilepsy

In parallel with the product launch, Zpeer Inc. has entered into a joint research agreement, effective November 27, 2025, with the Laboratory of Veterinary Clinical Pathology, Graduate School of Agricultural and Life Sciences, the University of Tokyo. The research will focus on generating more robust clinical evidence through structured clinical studies, including evaluation of seizure outcomes and quality of life (QOL) in affected dogs. The goal is to clarify the clinical relevance of high-concentration DHA as part of nutritional management strategies for canine epilepsy.

"Previous case observations suggested a potential role for DHA in reducing seizure frequency, but many clinical questions remain," said Associate Professor Yonezawa. "This collaboration will allow us to systematically evaluate its effects in real-world clinical settings and contribute more rigorous evidence to the field of veterinary neurology."

About A-DHA-PT™

A-DHA-PT™ is available in Japan through "Animato," Zpeer's veterinary e-commerce platform, which connects pet owners with products endorsed by their primary veterinary clinics. Owners must register their primary veterinary clinic to purchase the product.

About Zpeer Inc.

Zpeer Inc. develops veterinary informational, educational and commercial platforms and therapeutic solutions that support veterinary professionals and advance animal healthcare through clinical evidence and data-driven approaches. The company's mission is to help create a healthier future for both animals and the people who care for them.

Company Website: https://zpeer.info/en/

SOURCE Zpeer Inc.